Patent Assignment
Reel/Frame 029066/0655
Asset Transfer Agreement
Recorded: 2012-10-02
Pages: 86
Assignor
ELAN PHARMA INTERNATIONAL LIMITED
Executed: 2011-08-02
Assignee
EDT PHARMA HOLDINGS LIMITED
MONKSLAND, ATHLONE, COUNTY WESTMEATH, IRELAND
Covered Properties
(35)
Continuous Method of Grinding Pharmaceutical Substances
Patent:
5,718,388 →
Application:
08/249,787 →
Microprecipitation of Nanoparticulate Pharmaceutical Agents Using Surface Active Material Derived from Similar Pharmaceutical Agents
Patent:
5,716,642 →
Application:
08/370,928 →
Microprecipitation of Micro-Nanoparticulate Pharmaceutical Agents
Patent:
5,662,883 →
Application:
08/370,936 →
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers
Patent:
5,665,331 →
Application:
08/370,998 →
Dual Purposed Diagnostic/Therapeutic Agenthaving a Tri-Iodinated Benzoyl Group Linked to a Coumarin
Patent:
5,665,330 →
Application:
08/385,502 →
Nanoparticles Containing the R(-)Enantiomer of Ibuprofen
Patent:
5,718,919 →
Application:
08/393,648 →
Aerosols Containing Beclomethazone Nanoparticle Dispersions
Patent:
5,747,001 →
Application:
08/393,973 →
Method of Grinding Pharmaceutical Substances
Patent:
5,862,999 →
Application:
08/491,539 →
Novel 3-Amido-Triiodophenyl Esters as X-Ray Contrast Agents
Patent:
5,668,196 →
Application:
08/677,709 →
Reduction of Intravenously Administered Nanoparticulate-Formulation- Induced Adverse Physiological Reactions
Patent:
5,834,025 →
Application:
08/696,754 →
Polyether Copolymers and a Process for Preparing Them
Patent:
5,936,030 →
Application:
08/836,819 →
Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors Using Cellulosic Surface Stabilizers
Patent:
6,045,829 →
Application:
08/890,602 →
Nebulized Aerosals Containing Nanoparticulate Dispersions
Patent:
6,264,922 →
Application:
08/948,216 →
New Solid Dose Form of Nanoparticulate Naproxen
Patent:
6,165,506 →
Application:
09/148,332 →
Injectable Formulations of Nanoparticulate Naproxen
Patent:
6,153,225 →
Application:
09/154,422 →
Dry Powder Aerosols of Nanoparticulate Drugs
Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors Using Cellulosic Surface Stabilizers
Patent:
6,068,858 →
Application:
09/225,493 →
Methods of Treating Mammals Using Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors
Patent:
6,221,400 →
Application:
09/225,498 →
Use of Peg-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions
Patent:
6,270,806 →
Application:
09/261,151 →
Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticulate Compositions
Patent:
6,267,989 →
Application:
09/263,834 →
Controlled-Release Nanoparticulate Compositions
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Rapidly disintegrating solid oral dosage form
Patent:
6,316,029 →
Application:
09/572,961 →
Small-Scale Mill and Method Thereof
Patent:
6,431,478 →
Application:
09/583,893 →
Liquid Droplet Aerosols of Nanoparticulate Drugs
Patent:
6,811,767 →
Application:
09/597,738 →
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Small-Scale Mill and Method Thereof
Method of Using a Small Scale Mill
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Methods of Administering Liquid Droplet Aerosols of Nanoparticulate Drugs
Propellant-Based Nanoparticulate Dry Powder Aerosols and Method of Making
Controlled Release Nanoparticulate Clozapine Compositions
Application:
13/102,795 →
Publication:
US 2011/0300210
Rapidly Disintegrating Solid Oral Dosage Form
Application:
13/291,873 →
Publication:
US 2012/0114754
Methods of Administering Liquid Droplet Aerosols of Nanoparticulate Drugs
Application:
13/348,351 →
Publication:
US 2012/0183476
Dry Powder Aerosols of Nanoparticulate Drugs
Application:
13/404,790 →
Publication:
US 2012/0213829
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Patent Security Agreement (Second Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
Patent Security Agreement (First Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
Change of Name
Oct 2, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 029064/0645 →
Release by Secured Party (Second Lien)
Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
Property Transfer Agreement
Aug 12, 2014
From: ALKERMES PHARMA IRELAND LIMITED
To: ALKERMES SCIENCE ONE LIMITED
Reel/Frame 033522/0048 →
Change of Name
Mar 27, 2015
From: ALKERMES SCIENCE ONE LIMITED
To: DARAVITA LIMITED
Reel/Frame 035279/0701 →
Asset Transfer and License Agreement
Apr 10, 2015
From: ALKERMES PHARMA IRELAND LIMITED
To: DV TECHNOLOGY LLC
Reel/Frame 035410/0001 →
Business Transfer Agreement
Apr 10, 2015
From: DARAVITA LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 035409/0831 →
Security Interest
Apr 14, 2015
From: RECRO TECHNOLOGY LLC
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 035403/0288 →
Change of Name
Apr 16, 2015
From: DV TECHNOLOGY LLC
To: RECRO TECHNOLOGY LLC
Reel/Frame 035446/0904 →
Release of Security Interest
Apr 27, 2015
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: DARAVITA LIMITED (F/K/A ALKERMES SCIENCE ONE LIMITED, SUCCESSOR IN INTEREST TO ALKERMES PHARMA IRELAND LIMITED)
Reel/Frame 035505/0696 →
Security Interest
Nov 17, 2017
From: RECRO GAINESVILLE LLC
To: ATHYRIUM OPPORTUNITIES III ACQUSITION LP
Reel/Frame 044165/0783 →
Release of Security Interest
Nov 17, 2017
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: RECRO GAINESVILLE LLC (F/K/A RECRO TECHNOLOGY LLC)
Reel/Frame 044164/0008 →
Corrective Assignment to Correct the Receiving Party's Name Previously Recorded at Reel: 044165 Frame: 0783. Assignor(S) Hereby Confirms the Grant of Security Interest .
Mar 8, 2019
From: RECRO GAINESVILLE LLC
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 048540/0737 →
Assignment of Assignor's Interest
Jan 30, 2020
From: RECRO PHARMA, INC.
To: BAUDAX BIO, INC.
Reel/Frame 051671/0536 →
Assignment of Assignor's Interest
Jan 30, 2020
From: RECRO GAINESVILLE LLC
To: RECRO PHARMA, INC.
Reel/Frame 051670/0524 →
Security Interest
Jun 10, 2020
From: BAUDAX BIO N.A. LLC; BAUDAX BIO LIMITED; BAUDAX BIO, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052891/0590 →
Release of Security Interest
Dec 16, 2022
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: SOCIETAL CDMO GAINESVILLE, LLC
Reel/Frame 062123/0339 →
Release of Patent Security Agreement (First Lien)
Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →